Revenue segments as reported by the company.

Product, net

Revenue from anti-CD20 therapeutic programs

Other

Revenue from LEQEMBI Collaboration

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Amortization and impairment of acquired intangible assets

Collaboration profit sharing

(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations

(Gain) loss on fair value remeasurement of contingent consideration

Acquired in-process research and development

Restructuring charges

Other (income) expense, net

Gain on sale of building

Gain on sale of PRV

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biogen reports Q4 results, focuses on cost-saving and growth strategies

Biogen's Q4 2022 performance showed a revenue decline but an increase in non-GAAP diluted EPS.
The company is prioritizing cost-saving initiatives and strategic product launches for growth.
Challenges include managing expenses, evaluating R&D programs, and balancing cost reductions with investments.
Opportunities lie in upcoming product launches, potential acquisitions, and expanding into new therapeutic areas.

Biogen reports $2.5B revenue in Q1 2023, focuses on transformative drug launches

Biogen's Q1 2023 performance showed revenue stability despite challenges in MS product revenue.
The company's strengths lie in its focus on transformative drug launches and Alzheimer's research advancements.
Challenges include reimbursement expectations and managing the transition period until 2025.
Opportunities exist in external growth strategies, asset prioritization, and commercial launches for LEQEMBI and Zuranolone.

Biogen reports mixed Q2 earnings, LEQEMBI approval drives optimism

Biogen's Q2 2023 Earnings Call showcased mixed financial performance, with a focus on cost-saving initiatives and pipeline advancements. LEQEMBI's approval and positioning as a maintenance treatment offer promise, while challenges in revenue decline and market adoption persist. Strategic initiatives and upcoming milestones provide opportunities for growth and portfolio enhancement.

Biogen reports solid Q3 earnings, eyes regulatory approvals and market expansion

Biogen's Q3 2023 performance reflects steady growth, strategic initiatives, and promising product developments.
Strengths in sustainable growth priorities, product launches, and cost optimization position Biogen for long-term success.
Challenges in market expansion and operational efficiency require focused efforts on infrastructure and process improvements.
Opportunities in regulatory approvals, market expansion, and therapeutic advancements pave the way for future growth and innovation.

Biogen reports Q4 revenue decline but eyes growth opportunities

Biogen's Q4 2023 performance saw revenue decline offset by growth in rare disease revenue.
The company's strategic strengths lie in new product launches, cost reduction initiatives, and a focused pipeline strategy.
Challenges include bottlenecks in product launches and trial size reductions, while opportunities exist in upcoming milestones and market expansion.
Overall, Biogen aims for sustainable growth with a diversified product portfolio and strategic market focus.

Biogen reports robust Q1 earnings, focuses on market expansion

Biogen's Q1 performance reflects strong earnings growth and strategic focus on new launches. Despite challenges in launch processes, the company is capitalizing on market penetration opportunities. With a robust balance sheet and ongoing market expansion efforts, Biogen is poised for continued growth and success.

Biogen reports robust Q2 earnings, eyes growth in new launches

Biogen's Q2 2024 earnings call highlighted strong financial performance, successful product launches, and strategic priorities for growth. While challenges in the MS franchise persist, the company remains focused on sustainable growth through R&D investments and acquisitions. Opportunities for growth exist in expanding product portfolios and upcoming data releases.

Biogen reports mixed Q3 results, focuses on growth strategies

Biogen's Q3 2024 performance was mixed, with revenue growth in key products but overall revenue decline.
The company faces challenges in certain product segments but shows strength in new product development.
Opportunities lie in expanding market presence, new product launches, and potential business development.
Despite profitability challenges, Biogen's focus on growth strategies positions it for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Biogen has had a rollercoaster year, all down to the controversial approval of Aduhelm. Upon approval, its share price rocketed >$400, before a backlash against the approval and doubts raised over safety and efficacy drove it lower than at the beginning of 2021.

Biogen: All About Aduhelm Again In 2022, But Expecting Upside

Biogen Inc. (BIIB) closed at $235.41 in the latest trading session, marking a +0.4% move from the prior day.

Biogen Inc. (BIIB) Gains But Lags Market: What You Should Know

Biogen Inc. (BIIB) closed the most recent trading day at $234.48, moving -0.07% from the previous trading session.

Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know

Biogen has been one of the biggest U.S. blue-chip losers since June, mostly on troubles launching its first-to-market Alzheimer's drug.

The Bottom Fishing Club: Biogen

An advisory panel to the Japanese drug regulator is continuing deliberations on the new drug application filed by Biogen Inc. BIIB, -0.97% and partner Eisai Co. Ltd ESALY, +0.69% 4523, +1.21% , the companies said Wednesday. "The NDC (New Drugs Committee) is seeking additional data to be submitted as part of this process," said the statement.

Japan regulator to continue deliberations on Biogen and Eisai's Alzheimer's drug

CAMBRIDGE, Mass., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that the First Committee on New Drugs (NDC) of the Pharmaceutical Affairs and Food Sanitation Council that advises the Ministry of Health, Labour and Welfare (MHLW) in Japan has decided to continue deliberations on the application for the manufacturing and marketing approval of aducanumab for the treatment of Alzheimer's disease. The NDC is seeking additional data to be submitted as part of this process. The companies will continue to actively engage with the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan to agree on additional data requirements. Biogen and Eisai remain committed to bringing aducanumab to patients in Japan expeditiously.

Japan's First Committee on New Drugs of The Pharmaceutical Affairs and Food Sanitation Council Seeks Additional Data; Aducanumab Remains under Review

Biogen (BIIB) said it is lowering the wholesale acquisition cost (WAC) of Aduhelm by approximately 50%, effective Jan 1, 2022

Biogen (BIIB) to Cut Alzheimer's Drug Aduhelm Price by 50%

Biogen Inc.'s decision to cut the price of its Alzheimer's drug Aduhelm in half starting Jan. 1 is “a day late and a dollar short,” according to Raymond James, which is not expecting the move to change the trajectory of the drug launch or restore Biogen's battered reputation.

Biogen's decision to halve price of Alzheimer's drug is ‘a day late and a dollar short,' says Raymond James

In a surprise move, Biogen Inc (NASDAQ: BIIB) announced that it would slash the price of its controversial Alzheimer's drug Aduhelm in half from $56,000 to $28,000. In Q3, Biogen generated a mere 300k from Aduhelm sales, indicating that less than 100 Alzheimer's patients have received the drug.

After Much Criticism, Biogen Slashes Aduhelm Price In Half

Biogen Inc. BIIB, +0.81% said Monday it will reduce the price of its Alzheimer's drug aduhelm by 50% starting Jan. 1 in an effort to get it to more patients with early signs of the disease. "For a patient of average weight (74 kg), the yearly cost at the maintenance dose (10 mg/kg) will be $28,200," the company said in a statement.

Biogen to lower price of Alzheimer's drug aduhlem by 50% starting Jan. 1 to about $28,200 a year

The company to also implement cost-reduction measures. The company to also implement cost-reduction measures.

Biogen Announces Reduced Price for ADUHELM® to Improve Access for Patients with Early Alzheimer's Disease

Biogen (BIIB) expects to start the phase IV post-marketing confirmatory study of Aduhelm for Alzheimer's disease in 2022. It expects to complete the study in four years from the study initiation date.

Biogen (BIIB) to Begin Aduhelm Confirmatory Study in 2022

The European Medicines Agency has recommended the European Commission to reject Biogen Inc's (NASDAQ: BIIB) Aduhelm, an expected blow to its hopes of finding a widespread market for its struggling Alzheimer's drug. The EMA recommendation had been expected since the EMA's human medicines committee gave Biogen "a negative trend vote" after an oral presentation from the Company.

EMA's Committee Gives Thumbs Down To Biogen's Controversial Alzheimer's Drug, As Expected

Biogen and its partner Eisai Co said they would seek a re-examination of the opinion given by the European Medicines Agency.

Biogen Says EU Regulator Takes 'Negative Opinion' on Its Alzheimer's Drug

The stock price of Biogen Inc (NASDAQ: BIIB) fell by over 2.9% pre-market today. This is why it happened.

Biogen Stock (BIIB): Why The Price Fell Today

Biogen Inc. BIIB, -0.15% and partner Eisai Co. Ltd ESALY, +1.13% 4523, -2.11% said Friday an advisory committee to the European Medicines Agency has adopted a negative opinion on its Alzheimer's treatment aducanumab, known as aduhelm in the U.S. The company was seeking an authorization for the treatment in patients in the early stages of the disease known as mild cognitive impairment. "This decision is aligned to the negative trend vote of the committee in November 2021.

Biogen and Eisai say EU regulatory committee adopted negative opinion for its Alzheimer's treatment

Biogen to seek re-examination following CHMP negative opinion for aducanumab Biogen to seek re-examination following CHMP negative opinion for aducanumab

Update on Regulatory Submission for Aducanumab in the European Union

Biogen's Alzheimer's drug Aduhelm was approved for sale by the FDA in June. But whether or not it actually works is another question entirely.

Biogen's Alzheimer's Drug To Enter New Trial Stage Next Year

Biogen Inc. (BIIB) closed the most recent trading day at $235.52, moving -0.15% from the previous trading session.

Biogen Inc. (BIIB) Stock Moves -0.15%: What You Should Know

Biogen Inc (NASDAQ: BIIB) and Eisai Co Ltd (OTC: ESALY) are looking to get initial data from the FDA-mandated confirmatory trial for its Alzheimer's disease drug Aduhelm out in four years.  The companies will launch a global 1,300-person trial in May 2022 that will randomize early-stage Alzheimer's patients to receive either Aduhelm or a placebo.

Biogen Outlines Aduhelm's Confirmatory Trial Plans, Data Expected In 2026

Shares of Biogen Inc. BIIB, +2.22% gained 0.9% in premarket trading on Thursday after the company said it plans to submit a protocol for a Phase 4 confirmatory study for its Alzheimer's disease drug to U.S. regulators in March. The study is a condition of the accelerated approval granted to Aduhelm last year.

Biogen plans to start Phase 4 confirmatory study for Alzheimer's drug next year

CAMBRIDGE, Mass., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today provided an important update on the continuing progress of the Phase 4 post-marketing confirmatory study of ADUHELM® (aducanumab-avwa) 100 mg/mL injection for intravenous use in Alzheimer's disease.

Update on the Phase 4 Confirmatory Study of ADUHELM®

Bristol-Myers

Cameco

Equity Commonwealth

MasTec

Invitae

Muhlenkamp & Co. Inc., the investment firm founded by Ronald Muhlenkamp (Trades, Portfolio), released its portfolio for the third quarter earlier this month.

Muhlenkamp's Firm Buys Equity Commonwealth, Dumps 2 Stocks

CAMBRIDGE, Mass. and PARIS, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and TheraPanacea today announced that they have entered into a collaboration focused on multiple therapeutic areas in neuroscience, to further build on the companies' existing relationship. The aim is to leverage machine learning (ML) and artificial intelligence (AI) analysis to develop digital health solutions that may improve patient care, accelerate drug development, and further the understanding of the underlying pathologies of neurological diseases.

Biogen and TheraPanacea Announce New Collaboration with the Potential to Advance Digital Health for Personalized Medicine in Neuroscience

Between slow sales, safety concerns, and possible European rejection for Alzheimer's disease drug Aduhelm, Biogen Inc (NASDAQ: BIIB) is planning large-scale layoffs, STAT News reports, citing a Biogen employee close to the matter.  The publication writes that the plan has yet to be finalized and still needs approval from the company's board of directors.

News for Biogen Stock (BIIB)